Sona Nanotech Inc AI Stock Analysis
Want to see TSE:SONA full AI Analyst Report?
Sona Nanotech Inc (SONA) AI Stock Analysis
Sona Nanotech Inc
(CNQX:SONA)
The overall score of 37 indicates extreme risk and poor current performance, driven by Sona Nanotech's pre-revenue status, severe equity deficit, and strongly bearish price momentum. While management has curtailed the cash burn rate slightly, the fundamental necessity for external dilutive financing to maintain daily operations remains a dominant and pressing concern.
Sona Nanotech Inc (SONA) vs. iShares MSCI Canada ETF (EWC)
- Market Cap
- CAD 33.16M
- Dividend Yield
- ―
- Average Volume (3M)
- 50.10K
- Price to Earnings (P/E)
- -12.6
- Beta (1Y)
- 0.86
- Revenue Growth
- ―
- EPS Growth
- 24.65%
- Country
- Canada
- Employees
- 8
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Sona Nanotech Inc Business Overview & Revenue Model
Company Description
Based in Halifax, Canada, Sona Nanotech Inc. is a life sciences company focused on nanotechnology. It develops and commercializes gold nanorod solutions primarily for diagnostic applications. Their product portfolio includes the Nanotech COVID-19 Lat...
How the Company Makes Money
Sona Nanotech’s primary monetization approach is expected to be the sale and supply of its proprietary gold nanorods (and potentially related reagents/materials) for use by diagnostics and life-sciences customers in assay development and production,...
Sona Nanotech Inc Financial Statement Overview
Summary
Sona Nanotech is a pre-revenue biotechnology company exhibiting severe financial distress. Despite narrowing net losses over the past few years, the complete lack of top-line revenue, significant operational cash burn, and a deeply negative equity deficit present critical solvency risks.
Income Statement
10Very NegativeBalance Sheet
8Very NegativeCash Flow
15Very Negative| Breakdown | TTM | Jan 2026 | Jan 2025 | Jan 2024 | Jan 2023 | Jan 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -720.00K | -720.00K | -733.98K | -457.00K | -60.32K | -65.59K |
| EBITDA | -1.90M | -2.72M | -2.00M | -2.02M | -2.34M | -10.38M |
| Net Income | -2.44M | -3.25M | -2.70M | -2.50M | -2.36M | -10.77M |
Balance Sheet | ||||||
| Total Assets | 542.77K | 1.33M | 3.75M | 2.75M | 520.77K | 1.52M |
| Cash, Cash Equivalents and Short-Term Investments | 17.21K | 125.95K | 1.86M | 115.38K | 164.42K | 1.20M |
| Total Debt | 340.16K | 307.74K | 394.67K | 527.68K | 608.47K | 1.34M |
| Total Liabilities | 1.81M | 1.37M | 1.24M | 1.59M | 1.03M | 2.75M |
| Stockholders Equity | -1.26M | -38.78K | 2.51M | 1.16M | -507.86K | -1.22M |
Cash Flow | ||||||
| Free Cash Flow | -894.27K | -1.96M | -1.96M | -1.26M | -1.81M | -3.81M |
| Operating Cash Flow | -894.26K | -1.96M | -1.96M | -1.26M | -1.81M | -3.81M |
| Investing Cash Flow | 0 | 0 | 0 | 14.64K | 0 | 0 |
| Financing Cash Flow | 521.44K | 228.43K | 3.70M | 1.20M | 778 | 4.89M |
Sona Nanotech Inc Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:SONA, the sentiment is Negative. The current price of 0.27 is below the 20-day moving average (MA) of 0.28, below the 50-day MA of 0.32, and below the 200-day MA of 0.33, indicating a bearish trend. The MACD of -0.01 indicates Negative momentum. The RSI at 43.22 is Neutral, neither overbought nor oversold. The STOCH value of 30.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:SONA.
Sona Nanotech Inc Peers Comparison
Overall Rating
TSE:MIR47Neutral
TSE:EBM46Neutral
TSE:SONA37Underperform
TSE:BUX37Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 47Neutral | CAD 24.56M | -7.95 | 12.68% | ― | 45.72% | 35.82% | |
| 46Neutral | CAD 120.55M | -564.52 | 13.66% | ― | 36.59% | 43.33% | |
| 37Underperform | CAD 33.16M | -12.62 | 448.05% | ― | ― | 24.65% | |
| 37Underperform | CAD 44.72M | -31.11 | -250.77% | ― | -82.05% | 23.73% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TSE:SONA | Sona Nanotech, Inc | 0.27 | -0.24 | -47.06% | |
| TSE:BUX | BioMark Diagnostics | 0.42 | 0.07 | 20.00% | |
| TSE:EBM | Eastwood Bio-Medical Canada | 1.75 | 1.00 | 133.33% | |
| TSE:SZLS.H | Stagezero Life Sciences | 0.04 | 0.00 | 0.00% | |
| TSE:MIR | Medmira Inc | 0.04 | -0.04 | -50.00% | |
| TSE:ZYUS | Zyus Life Sciences Corporation | 0.40 | -0.29 | -42.03% |
Sona Nanotech Inc Corporate Events
Sona Nanotech Elevates CTO and Grants Options to Fund Cancer Therapy Push
PositiveSona Nanotech Inc. has appointed company co-founder and core technology co-inventor Dr. Kulbir Singh as Chief Technology Officer, formalizing his leadership role in advancing the firm’s Targeted Hyperthermia delivery system toward commercialization....
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 01, 2026
